focus test
rais pt revis outlook
rais price target maintain overweight rate
view abbott result goodal thing consid manag
withdrew guidanc cite uncertainti express comfort
street consensu note potenti better manag note
could provid updat outlook quarter guidanc second
half year maintain ep estim rais
ep estim believ abbott continu see uplift
test revenu revis pt maintain
tail busi hospit vs consumer-ori
abbott revenu broken two categori consumer-ori
sale establish pharma nutrit diabet collect sale
less like impact hospital/health facil
orient revenu like neg impact owe
postpon elect procedur reduc offic visit despit
increment revenu gener abbott diagnost test revenu
believ like challeng quarter abbott owe declin
like seen medic devic franchis except diabet due
postpon elect procedur
abbott three test high throughput test system
rapid point-of-car id instrument white hous state id
test use april serology/antibodi test
architect instrument abbott also work addit test review
test manufactur capac report
quarterli annual ep usd
rais usd
return equiti ttm
idc link barclay live interact chart
consensu number bloomberg receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight view share high-
qualiti growth asset believ compani
favor mix busi product
geograph perspect see medic devic
busi particularli diabet key driver
growth go forward believ growth profil
upsid case depend sever key factor
strong growth libr alin approv
adopt new product particularli within medic
devic abil drive margin expans
downsid case driven slower libre/alin
sale fx slowdown emerg market inabl
around likelihood healthcar reform
abbott deliv good quarter thing consid organ sale growth
pre-covid guidanc street/our estim reflect
strength establish pharma nutrit latter see
benefit consum stock pantri notabl us pediatr
expect sale perform weaker medic devic diagnost
given impact elect procedur postpon ep
ahead street/our estim expect initi guidanc
given on-going uncertainti regard manag withdrew
guidanc net/net continu view abbott rel safe believ
share maintain premium multipl maintain overweight rate
addit detail quarter
million except per share data chang sale constant currenc organ basi unless otherwis note
nutrit sale stronger expect reflect increas demand
late march ahead shelter place restrict particularli us pediatr
nutrit adult intern nutrit also strong
establish pharmaceut show strong growth broad-bas
perform across sever geographi manag note underli market
growth share dynam remain line histor trend
abbott three test two lab-bas
architect igg serolog test one point-of-car test id
test work increas manufactur test
manag note seen steadi improv procedur test
volum china cours march thu far april yet
pre-covid level volum low februari
expect sale perform medic devic diagnost
weaker due impact elect procedur postpon
abbott withdrew guidanc cite uncertainti regard
manag note may posit give qualit
updat sometim quarter may provid guidanc second
half express comfort consensu note thought could better
sale constant currenc organ basi divis
establish pharma nutrit medic devic
diagnost
gross margin y/i
sg sale y/i sale y/i
adjust tax rate y/i
adjust ep streets/our estim
abbott provid quarterli guidanc given uncertainti around although manag note expect
toughest quarter year especi core lab cardio neuro busi manag expect consum busi
establish pharma nutrit diabet continu perform line past trend
abbott withdrew annual guidanc cite uncertainti regard durat impact pandem
manag provid qualit commentari note expect toughest quarter expect see recoveri
especi elect procedur manag comment doesnt see procedur return pace
deceler though come back
actualsal laboratori management impact chang barclay abbott laboratori
compani report exclud sale
colleagu meehan life scienc tool diagnost barclay
test tracker color diagnost test trend estim
creat global diagnost test opportun billion rang
estim abbott price diagnost test serolog test
high-throughput test
march abbott receiv emerg use author eua assay
molecular system instrument
hospit academ center refer lab instrument run test per
day provid result hour abbott ship million
test manufactur million test per month
point-of-car test id
march abbott receiv eua test id instrument
isotherm nucleic acid amplif technolog id instrument point-of-car
system small lightweight boxdescrib compani size small
toaster abbott estim system place unit state
includ urgent care clinic hospit emerg room depart physician offic
test result posit return littl minut neg
abbott ramp product deliv test per day equat
million month ultim goal increas capac million test month
june higher beyond accord white hous april
test perform
earli april walgreen announc open drive id
test center expect other follow estim abbott charg around
test
serology/antibodi test architect
april abbott announc launch laboratory-bas antibodi blood test
plan begin ship april third test
test identifi igg antibodi bodi produc late
stage infect may remain month
initi test avail architect laboratori
instrument run test per hour
instrument use us laboratori
compani expect ship nearli million test first week million total
month april ship expect ramp million test us june
beyond
abbott also expect expand test run newer alin lab system
addit inform laboratori serolog test colleagu meehan- us
lifesci tool diagnost host expert call april dr robert
boorstein medic director lenco diagnost laboratori brooklyn focus
abbott plan expand expand laboratory-bas antibodi test detect igm
antibodi present new infect could indic patient current
infect viru test avail part fda notif without
emerg use author pathway abbott plan file eua submiss
fda receiv ce mark eu
abbott also plan develop later flow serolog test would point
care antibodi test similar pregnanc test
abbott mention antigen test compani could look develop
rapid antigen test well offer binaxnow influenza card vitro
immunochromatograph assay qualit detect influenza
nucleoprotein antigen nasopharyng np swab nasal swab sampl result
avail minut could also open rapid test capac
addit commentari abbott call well first look pleas see note
 kstew call note focus dx interest tidbit vol consensu
 first look put take across portfolio dx like focu
in-depth look pleas check deep dive examin near potenti long-
term rippl effect think investor visual novel coronaviru giant boulder
thrown lake creat big initi splash upon entri rippl seen felt reach far
shore time initi focu investor commun big splash creat near-term
effect import question difficult answer effect rippl
long-term impact healthcar industri wholeprovid physician patient insur
cours med-tech compani report aim
model pleas see barclay websit link
kristen stewart cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
